Cargando…

Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma

Mantle cell lymphoma (MCL) is a heterogeneous disease with a poor prognosis. Despite years of research in MCL, relapse occurs in patients with current therapeutic options necessitating the development of novel therapeutic agents. Previous attempts to pharmacologically inhibit SRC-3 show effectivenes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bijou, Imani, Liu, Yang, Lu, Dong, Chen, Jianwei, Sloan, Shelby, Alinari, Lapo, Lonard, David M., O’Malley, Bert W., Wang, Michael, Wang, Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029087/ https://www.ncbi.nlm.nih.gov/pubmed/36945511 http://dx.doi.org/10.21203/rs.3.rs-2653461/v1

Ejemplares similares

Novel targeted therapies for mantle cell lymphoma
por: Alinari, Lapo, et al.
Publicado: (2012)

Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date
por: Sawalha, Yazeed, et al.
Publicado: (2020)

PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma
por: Brown-Burke, Fiona, et al.
Publicado: (2023)

Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug
por: Song, Xianzhou, et al.
Publicado: (2015)

A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models
por: Chan, Wing Keung, et al.
Publicado: (2023)

Tumor Suppressor Role for the SPOP Ubiquitin Ligase in Signal-Dependent Proteolysis of the Oncogenic Coactivator SRC-3/AIB1
por: Li, Chao, et al.
Publicado: (2011)

SRC-2 Coactivator: a role in human metabolic evolution and disease
por: O’Malley, Bert W.
Publicado: (2020)

A genome-scale CRISPR Cas9 dropout screen identifies synthetically lethal targets in SRC-3 inhibited cancer cells
por: Gilad, Yosi, et al.
Publicado: (2021)

Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma
por: Lantermans, Hildo C., et al.
Publicado: (2020)

Steroid receptor coactivator 3 (SRC-3/AIB1) is enriched and functional in mouse and human Tregs
por: Nikolai, Bryan C., et al.
Publicado: (2021)

Emerging treatment options for the management of Hodgkin’s lymphoma: clinical utility of nivolumab
por: Bond, David A, et al.
Publicado: (2017)

Steroid receptor coactivators – their role in immunity
por: Gilad, Yosi, et al.
Publicado: (2022)

Wound Healing-related Functions of the p160 Steroid Receptor Coactivator Family
por: Mullany, Lisa K, et al.
Publicado: (2020)

Enhancer–promoter entanglement explains their transcriptional interdependence
por: Panigrahi, Anil K., et al.
Publicado: (2023)

An Aggressive Presentation of Mantle Cell Lymphoma With Unique Molecular Features
por: Inamdar, Arati A, et al.
Publicado: (2021)

Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma
por: Sureda-Gómez, Marta, et al.
Publicado: (2022)

Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironment
por: Han, Sang Jun, et al.
Publicado: (2022)

Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations
por: Gilad, Yosi, et al.
Publicado: (2021)

Targeting NSD2-mediated SRC-3 liquid–liquid phase separation sensitizes bortezomib treatment in multiple myeloma
por: Liu, Jing, et al.
Publicado: (2021)

Identification of Methylated Genes Associated with Aggressive Clinicopathological Features in Mantle Cell Lymphoma
por: Enjuanes, Anna, et al.
Publicado: (2011)

Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
por: Borgerding, Andrea, et al.
Publicado: (2009)

A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells
por: Hanel, Walter, et al.
Publicado: (2022)

Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas
por: Fleming, Megan, et al.
Publicado: (2022)

A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas
por: Jang, Ja-Young, et al.
Publicado: (2022)

Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma
por: Sircar, Anuvrat, et al.
Publicado: (2023)

P1250: EU-SOX11CCND1: A NOVEL IMMUNOCOMPETENT MURINE MODEL OF MANTLE CELL LYMPHOMA
por: Brown, F., et al.
Publicado: (2022)

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
por: Chilà, Rosaria, et al.
Publicado: (2014)

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
por: Vallumsetla, Nishanth, et al.
Publicado: (2015)

Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C
por: Lin, R J, et al.
Publicado: (2016)

EZH2 expression is associated with inferior overall survival in mantle cell lymphoma
por: Martinez-Baquero, Diana, et al.
Publicado: (2021)

Smoldering mantle cell lymphoma
por: Ye, Haige, et al.
Publicado: (2017)

Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma
por: Li, Lingzhi, et al.
Publicado: (2022)

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin's Lymphomas
por: Gunnellini, Marco, et al.
Publicado: (2012)

Classification of aggressive and classic mantle cell lymphomas using synchrotron Fourier Transform Infrared microspectroscopy
por: Kolodziej, Magdalena, et al.
Publicado: (2019)

Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination
por: Gilad, Yosi, et al.
Publicado: (2019)

Author Correction: Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination
por: Gilad, Yosi, et al.
Publicado: (2020)

Rac1 is a novel therapeutic target in mantle cell lymphoma
por: Tian, Tian, et al.
Publicado: (2018)

The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma
por: Ying, Zhi-Tao, et al.
Publicado: (2012)

Dual targeting of PI3K and BCL‐2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma
por: Ye, Haige, et al.
Publicado: (2022)

FNC efficiently inhibits mantle cell lymphoma growth
por: Zhang, Yan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1bigpssimfgme3cpp1mfg60tc3